Will Rentokil Shareholders Take Bid Bait?

Sir Gerry Robinson's interest in Rentokil has pushed the share price up 10%, but will shareholders take the bait?

John Stepek
By
published
in Features

Sir Gerry Robinson's interest in troubled hygiene services group Rentokil pushed the share price up 10% on Monday. But "will Rentokil shareholders really take the bait?" asks Robert Cyran on Breakingviews.com.

The company is a "poor buyout candidate." Buying the group would cost a buyer £4.7bn, assuming a 30% premium to its pre-bid share price, and with its debts included. But there isn't much in the way of asset value to back up a leveraged bid less than £700m in tangible assets, and "negative shareholders' equity to the tune of almost £600m". And let's not forget the £184m pension gap.

But the firm "spits out lots of cash", which means it could take on "at least some more debt", cutting its tax payments. And the business is "ripe for a turnaround."

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Any bid would likely take the form of "exchanging 1 Rentokil share for 0.9" shares in Raphoe, Sir Gerry's investment vehicle, says Barclays Stockbrokers, with Raphoe "effectively becoming the new' Rentokil".

But Rentokil's troubles will be tough to "overcome quickly as they stem from a long period of underinvestment in the business." And though there is "a chance" a private equity house might make a cash offer, Barclays puts this at less than 50%.

And of course, recent appointee Doug Flynn has yet to announce his first set of results, due Thursday 25th August. If they are good and he has a credible strategy, "the bid story will fade." Bad results would support the bid story, but investors then need to believe "Sir Gerry can grow a business in a worse state" than previously thought.

The Raphoe deal may be "superficially" attractive to shareholders, who would get some cash and "retain most of the upside" if a turnaround is achieved, says Cyran. But although details are unclear, it "looks like Robinson wants a large slug of the new company's equity" in return. His model will only work "if shareholders are completely fed up with existing management".

John Stepek
John Stepek

John Stepek is a senior reporter at Bloomberg News and a former editor of MoneyWeek magazine. He graduated from Strathclyde University with a degree in psychology in 1996 and has always been fascinated by the gap between the way the market works in theory and the way it works in practice, and by how our deep-rooted instincts work against our best interests as investors.

He started out in journalism by writing articles about the specific business challenges facing family firms. In 2003, he took a job on the finance desk of Teletext, where he spent two years covering the markets and breaking financial news.

His work has been published in Families in Business, Shares magazine, Spear's Magazine, The Sunday Times, and The Spectator among others. He has also appeared as an expert commentator on BBC Radio 4's Today programme, BBC Radio Scotland, Newsnight, Daily Politics and Bloomberg. His first book, on contrarian investing, The Sceptical Investor, was released in March 2019. You can follow John on Twitter at @john_stepek.

Latest